Quarterly ResultApr 28, 2026, 04:18 PM
CDNA Q1 Revenue +39% to $117.7M; Net Income $2.8M vs Loss
AI Summary
CareDx, Inc. reported a significant improvement in its first quarter 2026 financial results, achieving net income of $2.8 million, a substantial turnaround from a net loss of $10.4 million in Q1 2025. Total revenue increased by 39% to $117.7 million, driven primarily by strong growth in testing services and patient and digital solutions. The company also saw a positive shift in operating cash flow, providing $4.3 million compared to using $26.6 million in the prior year.
Key Highlights
- Total revenue increased 39% to $117.7 million in Q1 2026 from $84.7 million in Q1 2025.
- Net income was $2.8 million ($0.05 EPS) in Q1 2026, compared to a net loss of $10.4 million ($-0.19 EPS) in Q1 2025.
- Testing services revenue grew 47.6% to $91.4 million in Q1 2026.
- Patient and digital solutions revenue rose 33.5% to $16.0 million.
- Net cash provided by operating activities was $4.3 million in Q1 2026, a significant improvement from $26.6 million used in Q1 2025.
- Cash and cash equivalents increased to $77.9 million as of March 31, 2026, from $65.4 million at December 31, 2025.
- Litigation settlement expense decreased to $0.6 million in Q1 2026 from $5.4 million in Q1 2025.
- Company filed a petition for Supreme Court review regarding the Natera lawsuit on February 9, 2026.
Price Impact
More from CDNA